Evidence of significant contribution from CYP3A5 to hepatic drug metabolism

W Huang, YS Lin, DJ McConn, JC Calamia… - Drug metabolism and …, 2004 - ASPET
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity but can differ in
product regioselectivity and formation activity. To further explore this issue, we compared the …

Pharmacokinetics of tacrolimus during pregnancy

…, JG Umans, M Miodovnik, JC Calamia… - Therapeutic drug …, 2012 - journals.lww.com
Background: Information on the pharmacokinetics of tacrolimus during pregnancy is limited
to case reports despite the increasing number of pregnant women being prescribed …

lac permease of Escherichia coli: topology and sequence elements promoting membrane insertion.

J Calamia, C Manoil - … of the National Academy of Sciences, 1990 - National Acad Sciences
The membrane topology of Escherichia coli lac permease was analyzed using a set of 36 lac
permease-alkaline phosphatase (lacY-phoA) gene fusions. The level of enzymatic activity …

Tacrolimus placental transfer at delivery and neonatal exposure through breast milk

…, M Miodovnik, S Clark, JC Calamia… - British journal of …, 2013 - Wiley Online Library
Aim(s) The current investigation aims to provide new insights into fetal exposure to tacrolimus
in utero by evaluating maternal and umbilical cord blood (venous and arterial), plasma …

[HTML][HTML] Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content

…, M McDonald, B Prasad, T Wong, JC Calamia… - The …, 2016 - nature.com
Large interindividual variability has been observed in the metabolism of CYP2C19
substrates in vivo. The study aimed to evaluate sources of this variability in CYP2C19 activity, …

Measurement and Compartmental Modeling of the Effect of CYP3A5 Gene Variation on Systemic and Intrarenal Tacrolimus Disposition

…, CL Davis, Y Shitara, JC Calamia… - Clinical …, 2012 - Wiley Online Library
We evaluated the hypothesis that cytochrome P450 3A5 (CYP3A5) expression can affect
intrarenal tacrolimus accumulation. Tacrolimus was administered orally to 24 healthy …

Polymorphic human sulfotransferase 2A1 mediates the formation of 25-hydroxyvitamin D3-3-O-sulfate, a major circulating vitamin D metabolite in humans

…, RS Foti, B Prasad, A Chapron, J Calamia… - Drug Metabolism and …, 2018 - ASPET
Metabolism of 25-hydroxyvitamin D 3 (25OHD 3 ) plays a central role in regulating the biologic
effects of vitamin D in the body. Although cytochrome P450–dependent hydroxylation of …

Assessing Transporter‐Mediated Natural Product‐Drug Interactions Via In vitroIn Vivo Extrapolation: Clinical Evaluation With a Probe Cocktail

…, DL Hadi, S Bansal, JC Calamia… - Clinical …, 2021 - Wiley Online Library
The botanical natural product goldenseal can precipitate clinical drug interactions by inhibiting
cytochrome P450 (CYP) 3A and CYP2D6. Besides P‐glycoprotein, effects of goldenseal …

Simultaneous quantification of 25-hydroxyvitamin D3-3-sulfate and 25-hydroxyvitamin D3-3-glucuronide in human serum and plasma using liquid chromatography …

…, MZ Liao, Z Wang, T Wong, JC Calamia… - … of Chromatography B, 2017 - Elsevier
25-hydroxyvitamin D 3 -3-sulfate (25-OHD 3 -S) and 25-hydroxyvitamin D 3 -3-glucuronide (25-OHD
3 -G) are major conjugative metabolites of vitamin D 3 found in the systemic …

First-pass midazolam metabolism catalyzed by 1α, 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers

…, PB Watkins, P Schmiedlin-Ren, JC Calamia… - … of Pharmacology and …, 1999 - ASPET
Cytochrome P-450 (CYP) 3A4 accounts for approximately 50% of all P-450s found in the
small intestine ( Paine et al., 1997 ) and contributes to the extensive and variable first-pass …